Recruiting studies: Ensartinib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 1 location(s) · Tang-Du Hospital · NCT07354061 Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT05241028 Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
Phase 1/Phase 2 · 1 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT07448116 A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT05498064 Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Phase 3 · 1 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT05341583

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.